Grifols S A : on track to close its strategic alliance with Haier in first half 2024 May 6 2024

Grifols on track to close its strategic alliance

with Haier in first half 2024

• Both companies have completed the customary domestic and overseas government approval procedures; deal being finalized to close in June
• Through a share purchase agreement announced in December 2023, Grifols is selling a 20% equity stake in Shanghai RAAS (SRAAS) to Haier for RMB 12.5 billion (approximately USD 1.8 billion)
• The transaction is still subject to the compliance confirmation to be issued by the Shenzhen Stock Exchange
• Grifols and Haier will leverage their respective capabilities and work together to explore future business opportunities

Barcelona, Spain, May 6, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its strategic alliance with Haier Group (Haier), first communicated in December 2023, has met all customary conditions and is being finalized to close in June.

Both companies have completed the customary domestic and overseas government approval procedures. On March 1, Grifols informed that the period contractually established by the two companies for the completion of the confirmatory due diligence by Haier had concluded satisfactorily.

Through a share purchase agreement, Grifols is selling a 20% equity stake in Shanghai RAAS (SRAAS) to Haier for RMB 12.5 billion (approximately USD 1.8 billion) cash consideration. The proceeds will be applied to reducing Grifols secured debt obligations due in 2025.

Before the share transfer registration procedure can be processed at China Securities Depository and Clearing Co., Ltd, the transaction is still subject to the compliance confirmation to be issued by the Shenzhen Stock Exchange.

Grifols retains a significant 6.58% economic stake in SRAAS as well as a seat on its Board of Directors. SRAAS' 45% economic and 40% voting rights in Grifols Diagnostic Solutions (GDS), agreed to in 2020, stay the same.

As part of their agreement, Grifols and Haier will leverage their respective capabilities and work together to explore future business opportunities.

"Closing this strategic alliance with a global leader like Haier underscores the importance of China as a long-term growth market for Grifols," said Thomas Glanzmann, Grifols Executive Chairman. "Getting this done in the first half of the year, as we said we would, is another example of Grifols delivering on its commitments."

Page 1 of 3

Grifols retained Osborne Clarke, S.L.P. and JunHe LLP. as legal advisors. Nomura Securities International, Inc. serves as the lead financial advisor to Grifols.

INVESTORS:

Grifols Investors Relations & Sustainability [e-mail] [e-mail] - [e-mail]. [phone]

MEDIA CONTACT:

Grifols Press Office [e-mail].: [phone]

Spain

Duomo Comunication

Tel.: [phone]

Raquel Lumbreras (Tel. [phone])

[e-mail]

Borja Gómez (Tel. [phone])

[e-mail]

About Haier Group

Founded in 1984, Haier Group is a leading global provider of better life and digital transformation solutions. With users always at the center of its businesses, Haier has built 10 R&D centers, 71 research institutes, 35 industrial parks, 138 manufacturing centers and a sales network of 230,000 nodes around the world. Haier is the world's only IoT Ecosystem Brand that has been ranked in the Kantar BrandZ Top 100 Most Valuable Global Brands for five consecutive years. For more information about Haier Group, visit www.haier.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Page 2 of 3

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex- 35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Page 3 of 3